Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CTLA-4”

333 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 333 results

Testing effectiveness (Phase 2)WithdrawnNCT04149275
What this trial is testing

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Who this might be right for
Carcinosarcoma of OvaryCarcinosarcoma of UterusCarcinosarcoma of Vagina
University of Alabama at Birmingham
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Not applicableLooking for participantsNCT05332925
What this trial is testing

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Who this might be right for
Lung CancerNSCLCNSCLC Stage IV
Jun Zhang, MD, PhD 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT05014776
What this trial is testing

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 17
Early research (Phase 1)Study completedNCT01750580
What this trial is testing

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Who this might be right for
CANCER, NOS
Bristol-Myers Squibb 22
Testing effectiveness (Phase 2)Study completedNCT02643303
What this trial is testing

Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Who this might be right for
Head and Neck Squamous Cell CarcinomaBreast CancerSarcoma+8 more
Ludwig Institute for Cancer Research 58
Early research (Phase 1)Study completedNCT04572152
What this trial is testing

AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Akeso 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT05529316
What this trial is testing

Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Who this might be right for
Advanced Melanoma
Agenus Inc. 150
Early research (Phase 1)UnknownNCT05235438
What this trial is testing

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Who this might be right for
OncologyCTLA4 Haploinsufficiency
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 16
Early research (Phase 1)Study completedNCT02549651
What this trial is testing

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Who this might be right for
Diffuse Large B-Cell Lymphoma
MedImmune LLC 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Early research (Phase 1)Ended earlyNCT03674502
What this trial is testing

Safety of ADU-1604 in Adults With Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Aduro Biotech, Inc. 4
Testing effectiveness (Phase 2)UnknownNCT04544644
What this trial is testing

Combination Therapy in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Chinese PLA General Hospital 30
Early research (Phase 1)Study completedNCT00076934
What this trial is testing

Safety of RG2077 in Patients With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
National Institute of Allergy and Infectious Diseases (NIAID) 20
Testing effectiveness (Phase 2)Looking for participantsNCT06494995
What this trial is testing

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Fudan University 52
Not applicableNot Yet RecruitingNCT06155422
What this trial is testing

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Gang Chen (101199) 670
Testing effectiveness (Phase 2)WithdrawnNCT04007588
What this trial is testing

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage IV
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT02254772
What this trial is testing

A Phase I/II Study of Intratumoral Injection of SD-101

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+4 more
Robert Lowsky 9
Testing effectiveness (Phase 2)Looking for participantsNCT07315854
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital 32
Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Load More Results